Since NF-κB activation has been previously suggested to suppress TRAIL-induced apoptosis in pancreatic cancer cells [21], this finding suggested the potential for GSK-3 inhibition to sensitize pancreatic cancer to TRAIL. The gene discussed is NFKB1; the disease is pancreatic neoplasm.